NO20050841L - Pyrazolo [3,4-B] pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer - Google Patents

Pyrazolo [3,4-B] pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer

Info

Publication number
NO20050841L
NO20050841L NO20050841A NO20050841A NO20050841L NO 20050841 L NO20050841 L NO 20050841L NO 20050841 A NO20050841 A NO 20050841A NO 20050841 A NO20050841 A NO 20050841A NO 20050841 L NO20050841 L NO 20050841L
Authority
NO
Norway
Prior art keywords
sub
sup
optionally substituted
formula
inhibitors
Prior art date
Application number
NO20050841A
Other languages
English (en)
Inventor
Martin Redpath Johnson
Michael Dennis Dowle
Richard Graham Knowles
Alison Judith Redgrave
Peter Ward
Paul Spencer Jones
Caroline Mary Cook
Diane Mary Coe
Julie Nicole Hamblin
David George Allen
Christopher David Edlin
Mika Kristian Lindvall
Charlotte Jane Mitchell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0221455A external-priority patent/GB0221455D0/en
Priority claimed from GBGB0230045.7A external-priority patent/GB0230045D0/en
Priority claimed from GB0306595A external-priority patent/GB0306595D0/en
Priority claimed from GB0308017A external-priority patent/GB0308017D0/en
Priority claimed from GB0319708A external-priority patent/GB0319708D0/en
Priority claimed from GB0321074A external-priority patent/GB0321074D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20050841L publication Critical patent/NO20050841L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår en forbindelse med formel (I) eller et salt derav:hvor: RerC.alkyl,Ci.fluoralkyl, -CHCHOH eller -CHCHC0Ci.alkyl;. R 2 er et hydrogenatom (H), melyl eller Cjfluoralkyl;. Rer eventuelt substituert C3. gcykloalkyl eller eventuelt substituert mono-umettet C_cykloalkenyl eller en. eventuelt substituert. heterocyklisk gruppe med underformel (aa), (bb) eller (cc); hvor n' og n^ uavhengig er 1 eller 2; og hvor Y er O. S, S0eller NR; eller Rer en bicyklisk gruppe (dd) eller (ee); og hvor X er NRReller OR^ a. Forbindelsene er fosfodiesterase- (PDE) inhibitorer, spesielt PDE4-inhibitorer. Også 1 i 1 veiebragt er anvendelse av en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav, ved fremstilling av et medikament for behandling og/eller forebygging av en inflammatorisk og/eller allergisk sykdom hos et pattedyr så som el menneske, foreksempel kronisk obstruktiv lungesykdom (KOLS), astma eller allergisk 1 h i nitt.
NO20050841A 2002-09-16 2005-02-16 Pyrazolo [3,4-B] pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer NO20050841L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0221455A GB0221455D0 (en) 2002-09-16 2002-09-16 Compounds
GBGB0230045.7A GB0230045D0 (en) 2002-12-23 2002-12-23 Compounds
GB0306595A GB0306595D0 (en) 2003-03-21 2003-03-21 Compounds
GB0308017A GB0308017D0 (en) 2003-04-07 2003-04-07 Compounds
GB0319708A GB0319708D0 (en) 2003-08-21 2003-08-21 Compounds
GB0321074A GB0321074D0 (en) 2003-09-09 2003-09-09 Compounds
PCT/EP2003/011814 WO2004024728A2 (en) 2002-09-16 2003-09-12 Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
NO20050841L true NO20050841L (no) 2005-06-15

Family

ID=31999797

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050841A NO20050841L (no) 2002-09-16 2005-02-16 Pyrazolo [3,4-B] pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer

Country Status (23)

Country Link
US (2) US20060089375A1 (no)
EP (1) EP1539753B1 (no)
JP (1) JP2006503108A (no)
KR (1) KR20050052501A (no)
CN (1) CN100387598C (no)
AT (1) ATE442367T1 (no)
AU (1) AU2010201417A1 (no)
BR (1) BR0314392A (no)
CA (1) CA2497550A1 (no)
CY (1) CY1109619T1 (no)
DE (1) DE60329193D1 (no)
DK (1) DK1539753T3 (no)
ES (1) ES2331119T3 (no)
IL (1) IL166898A (no)
IS (1) IS7709A (no)
MA (1) MA27475A1 (no)
MX (1) MXPA05002887A (no)
NO (1) NO20050841L (no)
NZ (1) NZ538515A (no)
PL (1) PL375993A1 (no)
PT (1) PT1539753E (no)
SI (1) SI1539753T1 (no)
WO (1) WO2004024728A2 (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP2006503108A (ja) * 2002-09-16 2006-01-26 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
AU2004299277A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
GB0405933D0 (en) * 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
US20080275078A1 (en) * 2004-03-16 2008-11-06 Glaxo Group Limited Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
CA2561400A1 (en) 2004-04-02 2005-10-13 Glaxo Group Limited Chemical process and new crystalline form
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
DE602005011286D1 (en) * 2004-07-05 2009-01-08 Astellas Pharma Inc Pyrazolopyridinderivate
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20090131431A1 (en) * 2005-09-29 2009-05-21 Christopher David Edlin Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
BRPI0708337A2 (pt) 2006-02-28 2011-05-24 Helicon Therapeutics Inc pipirazinas terapêutica como inibidores pde4
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
PL2046787T3 (pl) 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2009041591A1 (ja) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
UY31636A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
AR070562A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091553A1 (es) 2008-02-06 2009-10-30 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
LT2899191T (lt) 2009-04-30 2017-10-25 Glaxo Group Limited Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
UY33373A (es) * 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
US9156791B2 (en) 2010-10-21 2015-10-13 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
RU2016112268A (ru) 2013-10-17 2017-11-22 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
DK3129023T3 (da) 2014-03-27 2021-05-25 Eicosis Llc Potente opløselige epoxidhydrolase-inhibitorer
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
JP6537601B2 (ja) 2015-05-12 2019-07-03 大鵬薬品工業株式会社 アザ二環式化合物の結晶
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
CN107964011A (zh) * 2016-10-19 2018-04-27 中国人民解放军军事医学科学院毒物药物研究所 取代吡唑并吡啶类衍生物及其医药用途
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
MY202326A (en) 2017-09-14 2024-04-24 Daiichi Sankyo Co Ltd Compound having cyclic structure
US11505559B2 (en) 2017-10-30 2022-11-22 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors
DK3717488T3 (da) * 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
IL300628A (en) * 2020-09-10 2023-04-01 Vanda Pharmaceuticals Inc Methods for the treatment of cyclic diseases or conditions-PDE IV
WO2025072040A1 (en) * 2023-09-28 2025-04-03 Merck Sharp & Dohme Llc Azaindazole derivatives useful as hcn2 modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598838A (en) * 1898-02-08 William b
US598973A (en) * 1898-02-15 Water-heater and smoke-consumer
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US4012373A (en) * 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) * 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP2006503108A (ja) * 2002-09-16 2006-01-26 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用
AU2004299277A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
CY1109619T1 (el) 2014-08-13
BR0314392A (pt) 2005-07-12
AU2003285300A1 (en) 2004-04-30
CN100387598C (zh) 2008-05-14
DK1539753T3 (da) 2010-01-04
EP1539753B1 (en) 2009-09-09
US20080175914A1 (en) 2008-07-24
DE60329193D1 (de) 2009-10-22
PT1539753E (pt) 2009-12-10
IS7709A (is) 2005-02-24
CN1694882A (zh) 2005-11-09
JP2006503108A (ja) 2006-01-26
ATE442367T1 (de) 2009-09-15
MA27475A1 (fr) 2005-08-01
WO2004024728A2 (en) 2004-03-25
EP1539753A2 (en) 2005-06-15
NZ538515A (en) 2007-04-27
PL375993A1 (en) 2005-12-12
SI1539753T1 (sl) 2009-12-31
ES2331119T3 (es) 2009-12-22
WO2004024728A3 (en) 2004-10-21
IL166898A (en) 2010-06-30
CA2497550A1 (en) 2004-03-25
AU2010201417A1 (en) 2010-04-29
MXPA05002887A (es) 2005-05-27
KR20050052501A (ko) 2005-06-02
US20060089375A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
NO20050841L (no) Pyrazolo [3,4-B] pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
NO20063340L (no) Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer
GEP20104973B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
SG179437A1 (en) Pyrimidine hydrazide compounds as pgds inhibitors
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
TNSN08478A1 (en) Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
NO20034311L (no) CCR5-antagonister for behandling av AIDS
DK2046787T3 (da) Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
ID27509A (id) Turunan piridin tersubstitusi-2,3 proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan senyawa-antaranya
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
WO2006011024A3 (en) New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
EA200970422A1 (ru) Аналоги пиразола
ATE289812T1 (de) Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen
MY135776A (en) PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
NO20082051L (no) Arylsubstituert, nitrogeninneholdende, heterofyklisk forbindelse
CN106065018B (zh) 取代的吲哚化合物及其使用方法和用途
RU2021103602A (ru) Производные тирозинамида в качестве ингибиторов rho-киназы